



Monitoring of hepatocellular carcinoma

Imen Akkari, Hanen Jaziri

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): D
Grade E (Poor): 0

P-Reviewer: Li LQ, China; Xing H, China

Received: October 3, 2023

Peer-review started: October 3, 2023

First decision: December 6, 2023

Revised: December 12, 2023

Accepted: February 1, 2024

Article in press: February 1, 2024

Published online: February 28, 2024



Imen Akkari, Department of Gastroenterology, University Hospital of Hached, University of Sousse, Faculty of Medicine of Sousse, Sousse 4000, Tunisia

Hanen Jaziri, Department of Gastroenterology, University Hospital of Sahloul, University of Sousse, Faculty of Medicine of Sousse, Sousse 4054, Tunisia

Corresponding author: Imen Akkari, MD, Associate Professor, Department of Gastroenterology, University Hospital of Hached, University of Sousse, Faculty of Medicine of Sousse, Rue Mohamed Karoui, Sousse 4000, Tunisia. imenakkaribm@gmail.com

Abstract

Screening for hepatocellular carcinoma in patients at risk is an evidence-based approach; however, adherence to the monitoring protocol recommended by international guidelines is difficult. Hence, there is a need to use the best screening options and refine the selection of patients at risk in the future.

Key Words: Hepatocellular carcinoma; Cirrhosis; Risk factors; Surveillance; Imaging; Diagnosis

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Hepatocellular carcinoma is a public health problem, and the majority of cases occur in patients with cirrhosis. The screening method for this disease has been the subject of several studies. This Editorial discusses the study titled "Hepatocellular carcinoma surveillance: An evidence-based approach" that was published in *World Journal of Gastroenterology* in 2019.

Citation: Akkari I, Jaziri H. Monitoring of hepatocellular carcinoma. *World J Gastroenterol* 2024; 30(8): 991-993

URL: <https://www.wjgnet.com/1007-9327/full/v30/i8/991.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v30.i8.991>

TO THE EDITOR

We read with great interest the article by Harris *et al*[1] on the surveillance of hepatocellular carcinoma (HCC). We agree with authors' insight that surveillance should be

performed in cirrhotic and high-risk hepatitis B patients to allow for earlier diagnosis of HCC; however, some issues need to be mentioned.

First, according to that study, the use of alpha-fetoprotein (AFP) in addition to ultrasound is thought to improve the sensitivity of HCC detection. Del Poggio *et al*[2] also recommend the use of AFP screening, as it guides the choice between the continuation of standard ultrasound or performing second-level imaging. However, this strategy is not recommended by European guidelines. The increased cost of screening is among the arguments against the addition of AFP[3]. On the other hand, it is well known that AFP has variable sensitivity and specificity according to its level, as altered levels can be noted without relationship to HCC and a high value has been reportedly observed in only 10%-20% of HCC cases in the initial stages[3,4]. Harris *et al*[1] cited another limitation of using this biomarker, namely the need to determine many thresholds depending on the sub-population.

Second, the use of other radiologic modalities for primary screening in obese persons and those with non-alcoholic fatty liver disease[1] seems to be very difficult to apply in real life. In addition to the radiation exposure that occurs with repeated computed tomography examinations, adherence to this screening program is also difficult as these imaging techniques are not easily accessible, particularly in developing countries. Contrast-enhanced ultrasound is a good surveillance option for patients at high risk for HCC[5]. Therefore, Harris *et al*[1] recommend the use of alternative imaging if the standard ultrasound is limited.

Third, Harris *et al*[1] reported that screening for HCC is underutilized in some demographics (non-Caucasian race and low socioeconomic status). In another study, < 2% of patients received guideline-concordant biannual HCC surveillance [6]. This deficiency in the screening program was detailed in the study by Del Poggio *et al*[2]. According to the authors, real-life implementation of screening programs is far from optimal; therefore, a new strategy was proposed to improve the detection of HCC by primary care physicians and involve performing surveillance in a subspecialist setting. The aim of this approach is to improve the results of real-life screening and reduce HCC mortality.

Finally, prediction models of patients at high risk for HCC[7] and artificial intelligence are emerging approaches in medicine that will be an important element in the management of liver diseases. These advances can be useful in screening patients at high risk for HCC development[8]. Refining the selection of patients at risk into sub-groups of very high, moderate, or low risk could improve HCC screening. The use of abdominal computed tomography and magnetic resonance imaging or better contrast-enhanced ultrasound, could serve as alternative methods in the high-risk population.

In summary, rigorous biannual monitoring by standard ultrasound of at-risk patients remains the first-line screening method. Artificial intelligence protocols to predict the development of HCC in at-risk patients could contribute to the selection of patients at high risk requiring a particular monitoring protocol.

FOOTNOTES

Author contributions: Akkari I designed the report; Jaziri H read and agreed to the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Tunisia

ORCID number: Imen Akkari 0000-0002-7953-6873; Hanen Jaziri 0000-0001-5527-3872.

S-Editor: Li L

L-Editor: A

P-Editor: Cai YX

REFERENCES

- 1 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. *World J Gastroenterol* 2019; **25**: 1550-1559 [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550]
- 2 Del Poggio P, Mazzoleni M, Lazzaroni S, D'Alessio A. Surveillance for hepatocellular carcinoma at the community level: Easier said than done. *World J Gastroenterol* 2021; **27**: 6180-6190 [PMID: 34712026 DOI: 10.3748/wjg.v27.i37.6180]
- 3 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; **69**: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]
- 4 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. *World J Clin Cases* 2019; **7**: 2269-2286 [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269]
- 5 Fetzter DT, Rodgers SK, Seow JH, Dawkins AA, Joshi G, Gabriel H, Kamaya A. Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma. *Radiol Clin North Am* 2019; **57**: 563-583 [PMID: 30928078 DOI: 10.1016/j.rcl.2019.01.004]

- 6 **Singal AG**, Tiro J, Li X, Adams-Huet B, Chubak J. Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. *J Clin Gastroenterol* 2017; **51**: 650-655 [PMID: [27870642](#) DOI: [10.1097/MCG.0000000000000708](#)]
- 7 **Guo J**, Gao XS. Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients. *World J Clin Cases* 2021; **9**: 3238-3251 [PMID: [34002133](#) DOI: [10.12998/wjcc.v9.i14.3238](#)]
- 8 **Masuzaki R**, Kanda T, Sasaki R, Matsumoto N, Nirei K, Ogawa M, Moriyama M. Application of artificial intelligence in hepatology: Minireview. *Artif Intell Gastroenterol* 2020; **1**: 5-11 [DOI: [10.35712/aig.v1.i1.5](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

